Oculis Holding AG Dossier - Source-backed chat

Oculis Holding AG

OCSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.49

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.76Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $486.4M

Enterprise Value $407.4M

Shares Outstanding 52.2M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Oculis Holding AG is in a transitional phase following a major clinical setback in late May 2026, when its lead candidate OCS-01 failed to meet primary endpoints in the Phase 3 DIAMOND-1 and DIAMOND-2 trials for diabetic macular edema (DME). This failure triggered a sharp stock decline and multiple shareholder investigations. However, the company's investment case is supported by a robust cash runway extending into the second half of 2029, which fully funds its remaining late-stage pipeline. Oculis has refocused its resources on two highly promising, first-in-class assets: Privosegtor (OCS-05) for optic neuropathies (which holds FDA Breakthrough Therapy and EMA PRIME designations) and Licaminlimab (OCS-02), a genotype-based precision medicine candidate for dry eye disease currently in the Phase 3 PREDICT-1 trial. While the pipeline remains fundamentally attractive, a 'Hold' recommendation is warranted until clinical clarity is established with the upcoming Licaminlimab readout in late 2026/early 2027 and the legal overhang from the DIAMOND failure is resolved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$22.12

Mean target$37.07

High · most bullish analyst$50.71

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$22.00

The bear case is triggered if Licaminlimab fails to show statistical significance in the PREDICT-1 trial, leaving the company reliant solely on the earlier-stage Privosegtor program. Additionally, escalating legal costs or adverse rulings from the ongoing securities investigations regarding the OCS-01 DIAMOND trials could deplete cash reserves faster than anticipated, forcing dilutive capital raises despite the projected 2029 runway.

Base CaseCentral scenario

$24.00

The base case reflects a gradual rebuilding of investor confidence. Oculis successfully executes the PREDICT-1 trial for Licaminlimab with data expected around late 2026 or early 2027, and initiates the PIONEER-1 trial for Privosegtor. The legal overhang from shareholder lawsuits remains a drag on valuation but does not result in catastrophic financial liabilities. The stock trades in a consolidated range, supported by its strong cash position of over CHF 213 million and long runway, but upside is capped until clinical proof-of-concept is delivered for the remaining pipeline.

Bull CaseUpside scenario

$23.00

The bull case assumes that Licaminlimab's biomarker-driven Phase 3 PREDICT-1 trial delivers positive topline results in late 2026, validating the first-ever precision medicine approach in dry eye disease. Concurrently, Privosegtor successfully advances through its PIONEER trials, leveraging its Breakthrough Therapy status to accelerate regulatory approval in optic neuritis. With a cash runway into 2H 2029, Oculis avoids near-term dilutive financing, and the stock recovers strongly as the market shifts focus from the DME failure to a highly differentiated ophthalmic portfolio.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with CHF 213 million in cash and short-term investments, providing a runway into 2H 2029.
Differentiated late-stage assets including Privosegtor, which holds FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis.
First-in-class genotype-based precision medicine approach with Licaminlimab in dry eye disease, targeting TNFR1-positive patients to maximize trial success probability.

Key Investment Risks

High clinical development risk, highlighted by the recent Phase 3 failure of OCS-01 in diabetic macular edema.
Legal and reputational risks stemming from multiple shareholder class-action investigations regarding the DIAMOND trial disclosures.
Pipeline concentration risk, as the company's valuation is now heavily dependent on the success of only two primary clinical assets.

Thesis Invalidation Triggers

Failure of Licaminlimab to meet primary efficacy endpoints in the Phase 3 PREDICT-1 trial.
Significant delays in patient recruitment or clinical holds placed on the Privosegtor PIONEER program.
Material adverse legal judgments or settlements related to the OCS-01 disclosure investigations that severely impact the cash runway.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.